Skip to main content

Hypertrophic Scars

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Etern Biopharma
Etern BiopharmaChina - Shanghai
1 program
1
ETD-001 gelPhase 21 trial
Active Trials
NCT07891416Not Yet Recruiting90Est. Dec 2027
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
Effectivity of Dermatix in Promoting Scar MaturationN/A1 trial
Active Trials
NCT00548210Unknown25

Trial Timeline

Clinical trial activity over time

2026
2027
Etern BiopharmaETD-001 gel

Clinical Trials (2)

Total enrollment: 115 patients across 2 trials

Phase II Clinical Study on Preliminary Efficacy and Safety of ETD-001 Gel for Hypertrophic Scars

Start: Feb 2027Est. completion: Dec 202790 patients
Phase 2Not Yet Recruiting
NCT00548210Bausch HealthEffectivity of Dermatix in Promoting Scar Maturation

Effectivity of Dermatix in Promoting Scar Maturation

25 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.